Sequenom Corp fka SQNM

[stockmule]

Not pretty, I am guessing they report a big loss Aug 5th and break below $2.74 in the weeks afters. Shucks there goes the bonus they usually give themselves. Wait I bet they do one anyway just because they want to keep themselves as irreplaceable employees, lol.

[insymbols]

$SQNM Sequenom Inc Inc Chart








http://pamphletshop.com

[stockmule]

Natera NTRA just IPO'd and is a $1B market cap company and Sequenom's biggest competition now. Most doctors are only going to use the low cost test and if something shows up might go for the full genome test. Couples are not going to pay the higher cost out of their pocket and obummacare won't.

[stockmule]

It's to point out that the competition is continuing to take away market share. People running the company have no clue and only react after the fact. They will bleed until they go out of business. The increase in shares (currency) are a desperate move to find a company to buy and distract from their failed leadership.

[martych]

This ruling was not a surprise which is why the stock didn't really react much incrementally. Sad for all molecular diagnostics co's as innovation is being undermined by courts but it is what it is.

[martych]

I'm not sure I understand the comment. The only test in US that is at a discount is Harmony from old Ariosa. That test is targeted for low risk which is why SQNM launched VisibiliT to screen for T18/21 with a risk score rather than a full scan.

Natera product Panorama shows a higher ASP than SQNM. Verify is at about the same cost as M21.

Real issues for SQNM:
1) terrible guidance that led to a Q1 miss and a reduced guidance for rest of year. Looks like it's driven by IP Pool with ILMN that reports revenues on a lag but regardless it was a VERY painful awakening.

2) NTRA S-1 shows they have substantial Y/Y growth in NIPT where SQNM has none.

Authorized shs were approved though no clue why they need so many.
Q2 likely not pretty but 2H should improve as the licensing pool starts to ramp.

NTRA will be very interesting to watch in q2 as well

[Bx3]

There may be one more problem, as appears to have been adequately decided in June 12,2015 Federal Circuit Court proceedings, involving suite #, or case # 14-1139 and 1144,Sequenom Vs. Ariosa ( can be googled) and apparently also Vs. Natera, that addressing possible patent infringement , it appears: court decision appears relative to a concept that the mentioned patent was on ineligible material and appears no infringement was made on Sequenom patent. If this is interpreted in error, please DD independently, always.

[stockmule]

Things are not so good now. Other tests are at a substantial discount to sqnm's. They don't get the whole genome only the T21 but that's what they want. Refinanced senior notes to push out the obligation one year but at what cost. All authorized shares are now accounted into the deal. No room to do anything unless more shares are authorized. The only option without more shares is to use cash and we know that's not going to happen, still losing money each Q. I wonder how long the havard grads can keep the ball in the air.

[martych]

SQNM has had a nice run over the past 18 months. Rally today related to ILMN conference call discussing sequential ramp of NIPT tests performed. They noted that much of this increase was from labs that had signed to do technology transfer to process tests themselves and were sending samples to ILMN until they were approved to run. These should fall into the IP pool which means SQNM will get a piece of the pie.

[stockmule]

They did a deal for cash but doubt they will get anything more from the other party but will pay a share of the tests going forward.
Maybe why Fazio is leaving, sees the writing on the wall. Good news is management will get a bonus as they moved the goal posts to make sure of it.

On January 20, 2015, John A. Fazio, who has served as a member of our Board of Directors since 2007, notified us that he has elected not to stand for re-election to our Board of Directors at our next annual meeting of shareholders. Mr. Fazio's decision not to stand for re-election to our Board of Directors does not involve any disagreement with us, our management or our Board of Directors.

[opticalalert_com]

"Last November, Ariosa, Illumina's Verinata Health and Natera scored deals to provide diagnostic testing to California women"

How come Sequenom was left out or will they be included later? Or are they already included in this program?

[stockmule]

They have added cash and reduced legal fees but my guess is not cash flow positive so stock continues to drop.

[crudeoil24]

End of day run takes SQNM to 52 wk. high.

[stockmule]

Cash infusion, no longer spending money on litigation (sad day for the attorneys) but can they expand the number of tests and collect on them.

[stockmule]

Roche buying Ariosa, 8000 lb gorilla now in the room

[pumper_stumper]

ROCHE ACQUIRES ARIOSA DIAGNOSTICS One of SQNMs main competitors.

If this company didn't have it bad enough, here is some really big news they are going to have to deal with.

Say hello to my little (now instantly big) friend!


(Reuters) Tue Dec 2, 2014 11:53am IST - Roche said on Tuesday it will acquire San Jose, CA-based Ariosa Diagnostics, Inc., a molecular diagnostics firm which makes a prenatal test to assess the risk of Down syndrome and other genetic abnormalities.

Financial details of the deal were not disclosed.

[pumper_stumper]

Friday brought some reason to that ridiculous rally off these multi month lows!

[pumper_stumper]

We are closing in on the two year anniversary of the last time an insider purchased with their own $!

If that doesn't tell you why to stay away from this, I don't know what will!

[pumper_stumper]

Hey stockmule, no there were no upgrades. Lots of "look for upgrades" but no, no upgrades. Thats what sqnm is about.. hope, not performance!

[stockmule]

Why would they be upgraded they never hit their projected target numbers. Maybe you have better news about what is going on, share it with the rest of us.

[pumper_stumper]

Really bad quarter there. Tests actually down year over year!

[pumper_stumper]

Lots of pain here over the long term. Amazing that this was a $100+ stock in the past!

[BlueRayn]

Look for an analyst upgrade overnight or tomorrow possibly.

[dubbya]

yes, a long one building too. A good reason to be optimistic here.

[jakebvt]

Possible bullish ascending triangle pattern on SQNM chart.

http://nuvesting.com/viewtopic.php?f=4&t=16&p=26#p26

[jakebvt]

I suspect big moves on this one. There is a triangle forming. Not sure which direction yet.

http://nuvesting.com/viewtopic.php?f=4&t=16&p=24#p24

[akamaii]

Sold 284 3000 shares. Up 8 gains one day I'm out. Market not stable if not I'd keep

[akamaii]

In for 3k shares @264

[dubbya]

Take that Ilumina:
http://www.fiercediagnostics.com/story/sequenom-scores-blow-against-illumina-their-prenatal-dx-patent-fight/2014-04-15?utm_medium=nl&utm_source=internal

[buckiii2]

SQNM STUDY just released: Noninvasive prenatal screening for fetal trisomies 21, 18, 13 and the common sex chromosome aneuploidies from maternal blood using massively parallel genomic sequencing of DNA
Noninvasive prenatal screening for fetal trisomies 21, 18, 13 and the common sex chromosome aneuploidies from maternal blood using massively parallel genomic sequencing of DNA

Objective

The objective of this study was to validate the clinical performance of massively parallel genomic sequencing (MPS) of cell-free DNA contained in specimens from pregnant women at high risk for fetal aneuploidy to test fetuses for trisomies 21, 18, 13, fetal sex and the common sex chromosome aneuploidies (45, X; 47, XXX; 47, XXY; 47, XYY).
Study Design

This is a prospective multicenter observational study of pregnant women at high risk for fetal aneuploidy who had made the decision to pursue invasive testing for prenatal diagnosis. Massively parallel single-read multiplexed sequencing of cfDNA was performed in maternal blood for aneuploidy detection. Data analysis was completed using sequence reads unique to the chromosomes of interest.
Results

3430 patients were analyzed for demographic characteristics and medical history. There were 137 fetuses with trisomy 21, 39 with trisomy 18, and 16 with trisomy 13 for a prevalence rate of the common autosomal trisomies of 5.8%. There were no false negative results for trisomy 21, three for trisomy 18 and two for trisomy 13; all three false positive results were for trisomy 21. Positive predictive values for trisomies 18 and 13 were 100% and for trisomy 21 was 97.9%. 8.6% of the pregnancies were 21 weeks or beyond; there were no aneuploid fetuses in this group. All 15 of the common sex chromosome aneuploidies (SCA) in this population were identified although there were 11 false positive results for 45,X. Taken together the positive predictive value for the SCA was 48.4% and the negative predictive value was 100%.
Conclusions

Our prospective study demonstrates that noninvasive prenatal analysis of cfDNA from maternal plasma is an accurate advanced screening test with extremely high sensitivity and specificity for trisomy 21 ( 99%) but with less sensitivity for trisomies 18 and 13. Despite high sensitivity, there was modest positive predictive value for the small number of common sex chromosome aneuploidies due to their very low prevalence rate. Less
Back To Board
Next topic

[calidude20]

Glad I Just saw this beautiful chart today

[TheFinalCD]

News Alert: Sequenom Laboratories grants Nicox exclusive promotion and marketing rights for its RetnaGene™ AMD test in North America

[Gratefullife]

Excellent news, what a surprise...why i have been in this subsector with CBMX since early last week.

http://ih.advfn.com/p.php?pid=nmona&article=60633043&symbol=SQNM

[martych]

$SQNM Pretty shady IMO. They have two analysts writing on stock. One that is a typical analyst, talking to management and looking at fundamentals (Quirk). They also have a technical view that comes out from a different analyst. This analyst (Johnson) only did technical analysis and concludes the stock is a sale because the chart is broken, while ignoring the newsflow and fundamentals.

News trumps technicals. Always has/always will. Let's see what next week brings us in updated fundamentals.

[Gratefullife]

This Piper downgrade: analysts do this in order to get shares cheaper.

Then they upgrade when they want to sell.

[Ovidius]

Marty, what kind of price appreciation do you see for 2014, first 1/2 and end of year. TIA

[lowman]

Problem is, Carna4z, there's no mods to this board, so nuttins gonna get stickied unless you become a mod and sticky it.

While you're at it, sticky MF's write-up.

Thanx

(as of 1/09/14, SQNM is surprisingly and unrealistically undervalued at the current AH pps of 2.76, given the news of the last 2 days)

[martych]

I've written a couple of blogs about SQNM. Here are the links. Hope they help.

http://seekingalpha.com/instablog/400846-marty-chilberg/2561101-sequenom-first-catalyst-is-eu-patent

http://seekingalpha.com/instablog/400846-marty-chilberg/2504801-sequenom-q4minus-13-do-you-feel-lucky



Also some articles if you don't know the background info:
http://seekingalpha.com/article/1478141-sequenom-disruptive-innovation-is-driving-investment-in-nipt

http://seekingalpha.com/article/1493382-sequenom-deciphering-the-business-model

http://seekingalpha.com/article/1859651-sequenom-is-the-bottom-in-the-rearview-mirror

[slim shaney]

Thank you for sharing. Our we expecting any approval news great financials I recently entered the stock and was about to sell but didn't. Martych any knowledge would be greatly appreciated. Thanks in advance.

[martych]

Thursday Jan 16th. 2PM Pac time

Terrible slot but with these press releases they should get some attendance

[Carna4z]

heads up to stickyville, http://ih.advfn.com/p.php?pid=nmona&article=60559092

[slim shaney]

When is the jp conference? Is it slotted for the 16 of this month

[Carna4z]

news in AH, a few extra million shorts to cover pronto!!! :) congrats!!!

[Carna4z]

the 'eod' candlestick will tell us a story, last run up was a multi day event. jpm conference in the near future... looks for 3.50's++ imo, of course. wont sell before then.

[Gratefullife]

Agreed, too soon to take profits here.

Like to see buying pressure take out resistance in the 2.80's in days ahead

[Carna4z]

just the beginning...

[martych]

January 1, 2014, the European Patent Office (:EPO) issued patent EP2183693 B1, entitled "Diagnosing Fetal Chromosomal Aneuploidy Using Genomic Sequencing," invented by Drs. Dennis Lo, Rossa Chiu, and Kwan Chee Chan of The Chinese University of Hong Kong. The patent claims novel methods for detecting fetal aneuploidy using sequencing and was the first patent filing made in the EPO directed to such novel methods. Sequenom holds exclusive rights to the patent, an important part of Sequenom's prenatal diagnostic patent portfolio, with coverage across all countries in the European Union, and also including Liechtenstein, Monaco, Norway and Switzerland.

[Ripping7]

$heff is also now on board. Be ready to sell at 10-15% gain. One he does and his $heep follow it pullback.

[Ripping7]

Time for take off. Should be a awesome week

[martych]

No reason to sell given the strength of rally. Daily bullish trading pattern continues. Still needs about 80% to get back to 120 day high which sold off on back Q2